EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes

Michael S Hughes, Francisco J Pasquel

Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 495-514

DOI: 10.1016/j.ecl.2026.04.015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Michael S Hughes und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Cir, Atlanta, GA, USA. E…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetic Nephropathies, Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 80 Literaturangaben. Gefördert von: NIDDK Division of Diabetes Endocrinology and Metabolic Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes-related kidney disease (DKD) is a major complication of type 1 diabetes (T1D) and remains a leading cause of kidney failure and cardiovascular risk. In this article, we summarize the biologic rationale and emerging clinical evidence for adjunctive kidney-protective therapies in T1D. We frame DKD pathophysiology in T1D around 3 interrelated domains: hyperglycemia-driven kidney stress, maladaptive tubular-glomerular hemodynamics and hyperfiltration, and inflammatory and fibrotic injury amplified by mineralocorticoid receptor signaling. The rapid growth in mechanistic understanding, clinical trial evidence, and early translation to T1D supports the incorporation of adjunctive kidney-protective therapies into the future management of DKD in T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetic NephropathiesGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsHumansAnimalsGastric Inhibitory PolypeptideMineralocorticoid Receptor AntagonistsNaphthyridines

Stichwörter der Autor:innen

Chronic kidney diseaseDKDDiabetes-related kidney diseaseFinerenoneGLP-1 receptor agonistsRenoprotectionSGLT inhibitorsType 1 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsfinerenoneSodium-Glucose Transporter 2 InhibitorsGastric Inhibitory PolypeptideMineralocorticoid Receptor AntagonistsNaphthyridines

Autor:innen und Institutionen

  • Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Cir, Atlanta, GA, USA. Electronic address: michael.s.hughes@emory.edu.
  • Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Cir, Atlanta, GA, USA. Electronic address: fpasque@emory.edu.

Förderung

  • NIDDK Division of Diabetes Endocrinology and Metabolic Diseases

Zitieren

APA

Hughes, M. S., & Pasquel, F. J. (2026). Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 495-514. https://doi.org/10.1016/j.ecl.2026.04.015

Vancouver

Hughes MS, Pasquel FJ. Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):495-514. doi:10.1016/j.ecl.2026.04.015

BibTeX
@article{Hughes2026,
  author = {Hughes, Michael S and Pasquel, Francisco J},
  title = {Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2026},
  volume = {55},
  number = {3},
  pages = {495--514},
  doi = {10.1016/j.ecl.2026.04.015}
}
Kostenlos starten →